Physician profile
Daniel L Davis
NPI 1114967353
$7,305.18
in general payments reported to CMS, 2019-2025
20 companies · $4,481 in 2025
The $4,481 reported for 2025 was more than what 89% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $141 · 2021: $957 · 2022: $83.44 · 2023: $497 · 2024: $548 · 2025: $4,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Travel and Lodging: $1,654 · Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Travel and Lodging | $1,654.27 |
| Food and Beverage | $1,371.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,356.46 | 2021-2025 | |
| Zimmer Biomet Holdings, INC. | $640.01 | 2021 | |
| Endogastric Solutions, INC | $564.66 | 2019-2023 | Esophyx |
| Angiodynamics, INC. | $285.57 | 2020-2024 | Solero |
| Medtronic, INC. | $256.36 | 2021-2024 | Endoflip |
| Boston Scientific Corporation | $154.03 | 2023-2024 | Jetstream Sc, Eluvia |
| Tela Bio, INC. | $129.23 | 2022-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| W. L. Gore & Associates, INC. | $124.46 | 2022-2023 | Gore Excluder Aaa Endoprosthesis |
| Pacira Pharmaceuticals Incorporated | $124.00 | 2021 | |
| Astellas Pharma US INC | $123.23 | 2025 | Veozah |
| Organogenesis INC. | $121.39 | 2023-2024 | Puraply |
| Endologix LLC | $85.54 | 2023-2024 | Alto Abdominal Stent Graft System, Afx2 Bifurcated Endograft System |
| Bolton Medical INC | $83.07 | 2024 | |
| Medtronic Vascular, INC. | $68.02 | 2019-2020 | |
| Penumbra, INC. | $49.42 | 2024 | Indigo System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $45.35 | 2025 | |
| Covidien LP | $29.90 | 2019 | |
| Depuy Synthes Sales INC. | $26.72 | 2021 | |
| Silk Road Medical, INC. | $19.25 | 2021 | |
| Bard Peripheral Vascular, INC. | $18.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.